Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRA | P10827 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1128691 | 0.83 | CA12 (0.47) | KDM4EALDH1A1LMNAMAPTTHRA | |
| SCHEMBL7661459 | 0.83 | CA12 (0.47) | LMNALTA4HMAPT | |
| SCHEMBL8761047 | 0.82 | ERN1 (0.57) | KDM4EALDH1A1LMNALTA4HCHRNB2 | |
| SCHEMBL29053405 | 0.80 | LMNA (0.41) | KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL289027 | 0.79 | LMNA (0.59) | KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL20556357 | 0.79 | THRA (0.48) | LMNATHRATHRB | |
| SCHEMBL8761425 | 0.79 | TRIM24 (0.57) | KDM4EALDH1A1LMNALTA4HCHRNB2 | |
| SCHEMBL1647021 | 0.79 | KDM4E (0.53) | KDM4EALDH1A1LTA4HCHRNB2CHRNA4 | |
| SCHEMBL4961552 | 0.79 | LMNA (0.47) | KDM4ELMNATHRA | |
| SCHEMBL31111369 | 0.78 | PDIA6 (0.40) | ALDH1A1LMNAMAPTTHRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621919-B1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-13 | — | — | EP | disclosed |
| EP-2621919-B1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-13 | — | — | EP | disclosed |
| US-8791129-B2 | Phenylquinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8791129-B2 | Phenylquinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8791129-B2 | Phenylquinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8552220-B2 | Therapeutic agent for Alzheimer's disease | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2621919-A1 | PHENYLQUINAZOLINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-08-07 | — | — | EP | disclosed |
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-11 | — | — | US | disclosed |
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-11 | — | — | US | disclosed |
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-11 | — | — | US | disclosed |
| CN-103119037-A | Phenyl quinazoline derivatives | MERCK PATENT GMBH | 2013-05-22 | — | — | CN | disclosed |
| WO-2012041435-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012041435-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-04-05 | — | — | WO | disclosed |
| CN-102046575-A | Therapeutic agent for alzheimer's disease | TOKYO INST TECH | 2011-05-04 | — | — | CN | disclosed |
| US-20110082295-A1 | NOVEL CURCUMIN DERIVATIVE | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-04-07 | — | — | US | disclosed |
| EP-2305629-A1 | THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | Tokyo Institute of Technology (JP) | 2011-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | HSP90B1, HSP90AB1, HSP90AA1 | KDM4E 3029/4885ALDH1A1 2843/4885LMNA 2423/4885 |
| US-20110082295-A1 | NOVEL CURCUMIN DERIVATIVE | BACE1, APP, BACE2 | KDM4E 1786/4885ALDH1A1 683/4885LMNA 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.